STEVEN MILLEN: Open Payments
NPI 1710182209 · ROCKINGHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 32 payments from 13 companies in 2025. Trend: 2023 $726 · 2024 $703 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $144 |
| Gilead Sciences, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
| Novo Nordisk Inc | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Viatris Specialty LLC | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
Products named: MOUNJARO, JARDIANCE, CAPLYTA, FARXIGA, TRELEGY ELLIPTA, YUPELRI, ZEPBOUND, INSPIRE.
Industry payments across NC — which companies pay providers there.
